Ipilimumab Combination Dosing: Less is More - @CCR_AACR Commentary from @MaxJLee & I to emphasize low-dose ipi as active & less toxic across multiple #melanoma trials now. I'm convinced & don't use the 3 mg/kg ipi dose anymore. @UPMCHillmanCC @PittHemeOnc https://t.co/DAEAUOEGd4

Important work from #TIIL PI Dr. @RiyueSunnyBao on immuno-genomic determinants of survival in neuroblastoma! Great work! https://t.co/nLQVXW9rvs

ML models in genomics are now routinely capable of generating 100-1000s of robust hypotheses - many/most of which are novel. It takes like months to validate one or a few of these & requires diverse expertise to make this happen 1/

@DrPaulyDeSantis @ASCO_pubs @DanielOlsonMD @Merck @NCCN @UPMCHillmanCC @MoffittNews @UCCancerCenter @MelanomaReAlli @CureMelanoma @MelanomaNetwork @MelanomaAction @MelanomaUK @saveyourskinfdn @PittDeptofMed These data suggest PD1+CTLA4 should be SOC in 1st or 2nd line & also seems to suggest PD1 + low dose ipi as a strong backbone for novel combos - LAG3? BRAF-MEK in high risk disease? @MaxJLee https://t.co/HDm9mVYAoh

Oncology phase I trials have been referred to as ‘toxicity trials’. The last decade has demonstrated that phase I trials have ORRs of ~20%, (this is within the range of ORRs of several FDA -approved drugs, making them potentially valid therapeutic options https://t.co/Lt24YRXQWd

Congrats #TIIL member @MaxJLee on @ASCO #ASCO21 Trial in Progress Poster! Phase I/II trial encorafenib+/-binimetinib+nivo+low-dose ipi in BRAF #melanoma. Attempting to tread the needle on efficacy vs tox in the highest risk pts. Huge translational potential in this study!

Statement @sitcancer #COVID19👇Insights from immuno-oncology: Access to #IL6 therapies (#tocilizumab, #sarilumab, #siltuximab) Pending peer review #JITC -#compassionateuse #clinicaltrials & IRB @US_FDA @genentech @Regeneron @sanofi @PAscierto @BernardAFox https://t.co/HafPnFHN21

Personalized Cancer Tmt: Cancer meets its nemesis in reprogrammed blood cells: http://t.co/GxTCgXTxMB @EricTopol